# UGX202 Injection in Patients With Advanced Retinitis Pigmentosa

> **NCT07311863** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Suzhou UgeneX Therapeutics Co., Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- Retinitis Pigmentosa (RP)

## Interventions

- **GENETIC:** UGX202 injection

## Key facts

- **NCT ID:** NCT07311863
- **Lead sponsor:** Suzhou UgeneX Therapeutics Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311863, "UGX202 Injection in Patients With Advanced Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07311863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*